Uppsala 27th Oct 2017


Nanexa expands its business opportunities with self-owned product project in the field of oncology.

 The decision on last monday’s meeting of shareholders to proceed with the new share issue proposed by the Board creates the financial opportunities for the company to start and run a product project on its own. The strategy extends opportunities for future revenue from product licensing, while the project will successfully deliver valuable results for the out-licensing of the PharmaShell® technology platform itself.

Nanexa has identified the oncology area as particularly interesting and already has contact with a number of experts in the field. The company aims to make more detailed decisions for the project in the first half of 2018, e.g., the choice of specific indication and active substance that matches an important medical need and significant market potential. The company then plans to document the project pre-clinical and prepare a first clinical study, to conduct with a partner or in-house.

“The recent results from both the development of the technology itself and the animal study results make us feel mature to take this important step,” said Nanexa’s CEO David Westberg.


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se



About Nanexa AB

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.